•  
  •  
  •  
  •  

2026-05-29 21:07:18

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • XTGlobal Infotech Limited Delivers Stellar Performance with ~39% Jump in PAT YoY
  • Mini Diamonds India Ltd announces Launch of Fancy Coloured LabGrown Diamond Jewellery Line through Namra Jewels Pvt Ltd
  • Gaudium IVF Delivers Record Q4FY26: Revenue, EBITDA and PAT
  • Unimech Aerospace and Manufacturing Ltd delivers strong Q4 FY26 Performance
  • EFC India Ltd reports strong results powering next phase of growth

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Indoco's formulation plant at Baddi - Plant III receives EU GMP certification
  • Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility
  • Lupin's Ankleshwar Facility Receives EIR from U.S. FDA
  • CDSCO grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH®
  • Supriya Lifescience Delivers Strong FY26 Performance; Q4 Revenue Surges 50% YoY
  • Zydus Therapeutics receives USFDA priority review to NDA for Saroglitazar
  • FDC Limited announces Q4 FY26 results
  • Morepen Labs Q4 Net Profit Rises 69%
  • Procter & Gamble Health announces results for the Fourth Quarter & Fiscal Year ended March 31, 2026
  • Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT
  • Fredun Pharmaceuticals Announces 2:1 Bonus Issue, Signaling Strong Growth Confidence
  • Fredun Pharmaceuticals Delivers Robust FY26 Performance
  • Gujarat Inject Kerala Ltd delivers robust FY26 performance, Net Profit rises 78% YoY
  • Classification of Unit-I of Eugia Pharma Specialities Ltd, Shameerpet as OAI
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • Lupin receives China Approval for Oseltamivir Phosphate Oral Suspension
  • Venus Remedies receives Saudi FDA approval for Plerixafor - its first Marketing Authorization for the specialty oncology therapy globally
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • Zydus Lifesciences Limited Financial Performance for Q4 & Full Year FY26
  • Senores Pharmaceuticals Ltd posts consolidated PAT of Rs. 36.67 crores in Q4FY26
  • Akums Drugs and Pharmaceuticals Ltd consolidated Q4 FY2025-26 profit at Rs. 87.40 crores
  • Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
  • GlaxoSmithKline Pharmaceuticals Ltd announces Q4, FY26 results

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • XTGlobal Infotech Limited Delivers Stellar Performance with ~39% Jump in PAT YoY
  • Mini Diamonds India Ltd announces Launch of Fancy Coloured LabGrown Diamond Jewellery Line through Namra Jewels Pvt Ltd
  • Gaudium IVF Delivers Record Q4FY26: Revenue, EBITDA and PAT
  • Unimech Aerospace and Manufacturing Ltd delivers strong Q4 FY26 Performance
  • EFC India Ltd reports strong results powering next phase of growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025